You are viewing the site in preview mode

Skip to main content


A novel fully human monoclonal antibody that neutralizes multiple human IFN-α subtypes effectively: a candidate therapy for SLE

Systemic lupus erythematosus is a chronic, heterogeneous autoimmune disease, and there is no specific drug for its effective treatment, which may be because of its complexity on pathogenic mechanism. A multitude of studies of SLE in the last decade have accentuated a central role of the interferon-alpha (IFN-α) pathway in SLE pathogenesis. And the Clinical Trials have proved the effectiveness of antibodies targeting multiple human IFN-α subtypes, especially the sifalimumab of AstraZeneca (IIb). A novel fully human antibody that neutralizes multiple human IFN-α subtypes effectively was screened from fully synthetic human antibody library by Institute of Biotechnology, Academy of Military Medical Sciences. The antibody could effectively neutralize all the 12 subtypes except of IFN-α7, and its epitope is thoroughly distinct from others on research, which made its neutralizing spectrum different, and neutralizing efficacy stronger.

Author information

Correspondence to Shuang Wang.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark


  • Public Health
  • Clinical Trial
  • Monoclonal Antibody
  • Systemic Lupus Erythematosus
  • Effective Treatment